Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 11/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240219 | 0.94 | GRIA2 (0.42) | ADAMTS4GRIA2KCNH2GRIA4PGR | |
| SCHEMBL6242831 | 0.89 | GRIA2 (0.52) | GRIA2KCNH2GRIA4GRIA1GRIA3 | |
| SCHEMBL6243805 | 0.84 | GRIA4 (0.44) | ADAMTS4GRIA2KCNH2GRIA4 | |
| SCHEMBL6245808 | 0.83 | CA12 (0.41) | GRIA2KCNH2 | |
| SCHEMBL6236867 | 0.83 | ADAMTS4 (0.40) | ADAMTS4PGRMCOLN3CCR6ACLY | |
| SCHEMBL6241979 | 0.82 | GRIA4 (0.51) | GRIA2KCNH2GRIA4GRIA1GRIA3 | |
| SCHEMBL6239372 | 0.80 | GRIA2 (0.60) | GRIA2KCNH2 | |
| SCHEMBL6246774 | 0.79 | GRIA2 (0.60) | ADAMTS4GRIA2KCNH2 | |
| SCHEMBL6240220 | 0.77 | MCOLN3 (0.38) | ADAMTS4PGRMCOLN3CCR6ACLY | |
| SCHEMBL6239207 | 0.77 | GRIA4 (0.44) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | CANTELL BUDDY EUGENE (US) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | GRIN2B, GRIN2A, GRIN1 | ADAMTS4 3846/4885GRIA2 7/4885KCNH2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.